使用分化的人类诱导多能细胞的基于细胞的检测方法。

Cell-Based Assays Using Differentiated Human Induced Pluripotent Cells.

作者信息

Cader Zameel, Graf Martin, Burcin Mark, Mandenius Carl-Fredrik, Ross James A

机构信息

Translational Molecular Neuroscience Group, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.

Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.

出版信息

Methods Mol Biol. 2019;1994:1-14. doi: 10.1007/978-1-4939-9477-9_1.

DOI:10.1007/978-1-4939-9477-9_1

PMID:31124100

Abstract

This chapter describes the requirements and preconditions for using human induced pluripotent cell lines in assay development within the pharmaceutical industry. The joint collaborative effort between academic and pharma partners within the StemBANCC consortium which enabled the implementation of iPSC-derived cellular models for drug discovery is highlighted. This large collaborative scientific network has successfully derived a significant number of well-characterized patient-specific iPSC lines and established disease-relevant cellular assays, both of which are requirements for enabling pharmaceutical companies to develop more efficacious and safer medicines.

摘要

本章描述了在制药行业的分析方法开发中使用人诱导多能干细胞系的要求和前提条件。重点介绍了StemBANCC联盟中学术伙伴与制药伙伴之间的联合协作努力，该努力促成了用于药物发现的诱导多能干细胞衍生细胞模型的实施。这个大型协作科学网络已成功获得了大量特征明确的患者特异性诱导多能干细胞系，并建立了与疾病相关的细胞分析方法，这两者都是制药公司开发更有效、更安全药物的必要条件。